Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) 12-1 Month Momentum % : -19.31% (As of May. 02, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-02), Ironwood Pharmaceuticals's 12-1 Month Momentum % is -19.31%.

The industry rank for Ironwood Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

IRWD's 12-1 Month Momentum % is ranked worse than
63.9% of 1119 companies
in the Drug Manufacturers industry
Industry Median: -7.06 vs IRWD: -19.31

Competitive Comparison of Ironwood Pharmaceuticals's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ironwood Pharmaceuticals's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's 12-1 Month Momentum % falls into.

Ironwood Pharmaceuticals (NAS:IRWD) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ironwood Pharmaceuticals (NAS:IRWD) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Ironwood Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

I76:Germany I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Executives

Marla L Kessler	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis	officer: SVP, Chief Business Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany	officer: SVP, Chief Financial Officer	100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver	officer: Principal Accounting Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John	officer: Chief Legal Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt	officer: Chief Commercial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline	officer: CMO,SVP,Head-Res&Drug	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard	officer: SVP, Chief Operating Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman	officer: Chief Accounting Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor	officer: SVP, GC & Secretary	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110